GlassScriptPhysician profile
Demosthenes Papamatheakis
NPI 1326168600
$24,365.91
in general payments reported to CMS, 2019-2025
9 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $10K · 2021: $1,807 · 2022: $282 · 2023: $247 · 2024: $542 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.30 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $22,994.54 | 2019-2024 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $614.96 | 2019-2025 | |
| United Therapeutics Corporation | $508.10 | 2020-2025 | Tyvaso, Tyvaso, Orenitram |
| Merck Sharp & Dohme LLC | $76.74 | 2022-2024 | Winrevair |
| Sandoz INC. | $61.53 | 2019-2022 | |
| Abiomed | $45.46 | 2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.67 | 2019 | |
| Scpharmaceuticals INC. | $21.69 | 2023 | |
| La Jolla Pharmaceutical Company | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demosthenes Papamatheakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.